A detailed history of Millrace Asset Group, Inc. transactions in Castle Biosciences Inc stock. As of the latest transaction made, Millrace Asset Group, Inc. holds 49,773 shares of CSTL stock, worth $1.08 Million. This represents 1.11% of its overall portfolio holdings.

Number of Shares
49,773
Previous 78,914 36.93%
Holding current value
$1.08 Million
Previous $1.7 Million 35.29%
% of portfolio
1.11%
Previous 1.69%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

SELL
$18.06 - $25.3 $526,286 - $737,267
-29,141 Reduced 36.93%
49,773 $1.1 Million
Q4 2023

Feb 12, 2024

BUY
$12.19 - $22.43 $19,491 - $35,865
1,599 Added 2.07%
78,914 $1.7 Million
Q3 2023

Nov 13, 2023

BUY
$13.28 - $20.3 $1.03 Million - $1.57 Million
77,315 New
77,315 $1.31 Million
Q3 2022

Oct 31, 2022

BUY
$22.51 - $34.32 $1.43 Million - $2.17 Million
63,345 New
63,345 $1.65 Million

Others Institutions Holding CSTL

About CASTLE BIOSCIENCES INC


  • Ticker CSTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 26,297,000
  • Market Cap $572M
  • Description
  • Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...
More about CSTL
Track This Portfolio

Track Millrace Asset Group, Inc. Portfolio

Follow Millrace Asset Group, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Millrace Asset Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Millrace Asset Group, Inc. with notifications on news.